Diabetes Pro Quarterly - Winter 2014 - (Page 1)

WInTeR 2014 DiabetesPro Quarterly A m e r i c A n D i A b e t es A s s o c i At i o n n e w s fo r P r o f es s i o n A l m e m b e r s Innovative Researchers granted Association's first 'Pathway to stop Diabetes' Awards To accelerate the research needed to discover new ways to combat diabetes, the American Diabetes Association's Pathway to Stop Diabetes® initiative aims to fund 100 new diabetes researchers over the next decade. The first group of researchers who will receive grant support through this program were announced in early January. Pathway awards are available in two grant types, each providing up to $1.625 million in support for research. The Initiator Award, intended for scientists currently in training positions, offers two separate phases that provide support through the transition to independence, for a total of up to seven years of funding. The Accelerator Award provides five years of support to exceptional scientists who are either early in their independent diabetes research careers or well established in other disciplines but interested in applying their expertise to diabetes research. In ThIs Issue new standards of Care Reflect Trend Toward Individualized Care 4 The first five awards, representing $8.125 million in grants, are outlined below. 2014 gRAnT ReCIPIenTs Prince hall shriners Donate to help African Americans Manage Their Diabetes 9 74th scientific sessions Program Overview 10 January 2014 Research Awards Announced 13 INITIATOR AWARDS Michael Dennis, PhD Pennsylvania State University, Hershey, Pa. Hyperglycemia-Induced Translational Control of Gene Expression in the Retina Nearly all people with type 1 diabetes, and the majority with type 2, experience some degree of retinopathy in their lifetime. Unfortunately, treatments that fully address the molecular pathogenesis of this complication are presently lacking. The overall goal of this research project is to identify mechanisms that regulate hyperglycemia-induced expression of factors that control blood vessel growth and proliferation in the retina. This research strategy represents a new and fundamentally different approach to investigate the molecular players responsible for retinal neurovascular complications, and will allow validation of novel targets for intervention at the level of gene expression. This study may ultimately lead to the development of innovative, nondestructive therapies that address the cause of diabetic retinopathy. continued on page 2 PROfessIOnAl.DIAbeTes.ORg http://PROFESSIONAL.DIABETES.ORG

Table of Contents for the Digital Edition of Diabetes Pro Quarterly - Winter 2014

Contents

Diabetes Pro Quarterly - Winter 2014